Kathleen M Moore (Kathleen N Moore, Kathleen Moore)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 34

Top Topics

Newly Diagnosed

Chemotherapy Induced

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Future oncology (London, England)

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Paul A DiSilvestro, Cara A Mathews, David G Mutch, Marcia L Hernandez, Lainie P Martin, Erin Bishop, Sarah E Gill, Mary E Gordinier, Robert A Burger, Carol Aghajanian, Joyce F Liu, Kathleen M Moore, Michael A Bookman
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (21) (2024)
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Paul A DiSilvestro, Cara A Mathews, David G Mutch, Marcia L Hernandez, Lainie P Martin, Erin Bishop, Sarah E Gill, Mary E Gordinier, Robert A Burger, Carol Aghajanian, Joyce F Liu, Kathleen M Moore, Michael A Bookman
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Debra L Richardson, Julia Coelho França Quintanilha, Natalie Danziger, Gerald Li, Ethan S Sokol, Alexa B Schrock, Ericka M Ebot, Neeru Bhardwaj, Tanesha Norris, Anosheh Afghahi, Anthony Frachioni, Christina R Washington, Lauren Dockery, Julia A Elvin, Ryon P Graf, Kathleen M Moore
Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Paul A DiSilvestro, Cara A Mathews, David G Mutch, Marcia L Hernandez, Lainie P Martin, Erin Bishop, Sarah E Gill, Mary E Gordinier, Robert A Burger, Carol Aghajanian, Joyce F Liu, Kathleen M Moore, Michael A Bookman
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (21) (2024)
Kathleen M Moore, Mansoor R Mirza, Charlie Gourley, Sandro Pignata, Domenica Lorusso, Bradley J Monk, Jalid Sehouli, Jeanne M Schilder, Nathalie D'Esquermes, Antonio Gonzáles Martin
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Paul A DiSilvestro, Cara A Mathews, David G Mutch, Marcia L Hernandez, Lainie P Martin, Erin Bishop, Sarah E Gill, Mary E Gordinier, Robert A Burger, Carol Aghajanian, Joyce F Liu, Kathleen M Moore, Michael A Bookman
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Charles N Landen, Luciana L Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller, Kathleen M Moore, Cagatay Taskıran, Michael A Bookman, Kristina Lindemann, Charles Anderson, Regina Berger, Tashanna Myers, Mario Beiner, Thomas Reid, Els Van Nieuwenhuysen, Andrew Green, Aikou Okamoto, Carol Aghajanian, Premal H Thaker, Stephanie V Blank, Victor K Khor, Ching-Wei Chang, Yvonne G Lin, Sandro Pignata
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Rachel N Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L Coleman, Felix Hilpert, Amit M Oza, Anneke M Westermann, Martin K Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, David Cibula, Kathleen M Moore, Josep M Del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M O'Malley, Cristina Churruca, Gunnar B Kristensen, Andrew R Clamp, John Farley, Gopakumar V Iyer, Isabelle L Ray-Coquard, Bradley J Monk
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Erika Paige Hamilton, Judy S Wang, Amit M Oza, Manish R Patel, Susanna V Ulahannan, Todd M Bauer, Janet L Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova, Ganesh Moorthy, Maureen M Hattersley, Gillian M Littlewood, Patrick D Mitchell, Jamal Saeh, Gayle P Pouliot, Kathleen M Moore
First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. Molecular cancer therapeutics (2023)
Thomas J Herzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven, Lynn R Kong, Nidhi Kumar Tyagi, Grainger S Lanneau, Beverly J Long, Robert L Marsh, Shelly M Seward, David C Starks, Stephen Welch, Kathleen M Moore, Panagiotis A Konstantinopoulos, Lucy Gilbert, Bradley J Monk, David M O'Malley, Xiwei Chen, Rita Dalal, Robert L Coleman, Jalid Sehouli
ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future oncology (London, England) (2023)
Xiang Yin, Ruthanna C Davi, Elizabeth B Lamont, Premal H Thaker, William H Bradley, Charles A Leath, Kathleen M Moore, Khursheed Anwer, Lauren Musso, Nicholas Borys
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. JCO clinical cancer informatics 7 (2023)
Todd M Bauer, Kathleen M Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, J Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Sarah A Cook, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne F Jones, David R Spigel, Siqing Fu
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted oncology (2023)
Desiree R Azizoddin, Amy M Cohn, Susanna V Ulahannan, Christina E Henson, Adam C Alexander, Kathleen M Moore, Laura L Holman, Laili Kharazi Boozary, Munjireen S Sifat, Darla E Kendzor
Cannabis use among adults undergoing cancer treatment. Cancer (2023)
Xiang Yin, Ruthanna C Davi, Elizabeth B Lamont, Premal H Thaker, William H Bradley, Charles A Leath, Kathleen M Moore, Khursheed Anwer, Lauren Musso, Nicholas Borys
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. JCO clinical cancer informatics 7 (2023)
Xiang Yin, Ruthanna C Davi, Elizabeth B Lamont, Premal H Thaker, William H Bradley, Charles A Leath, Kathleen M Moore, Khursheed Anwer, Lauren Musso, Nicholas Borys
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. JCO clinical cancer informatics 7 (2023)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, David M O'Malley, Ana Oaknin, Michelle K Wilson, Robert L Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkiran, Olga Mikheeva, Oladapo O Yeku, Anita Chudecka-Glaz, Michael Schenker, Ramey D Littell, Tamar Safra, Hung-Hsueh Chou, Mark A Morgan, Vít Drochýtek, Joyce N Barlin, Toon Van Gorp, Frederick Rand Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile C Collins, Kathleen M Moore, Frederic Marmé, Shannon Neville Westin, Iain A McNeish, Danny Shih, Kevin K Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca S Kristeleit
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (34) (2022)
Matthew A Powell, Virginia L Filiaci, Martee L Hensley, Helen Q Huang, Kathleen M Moore, Krishnansu S Tewari, Larry J Copeland, Angeles A Secord, David G Mutch, Alessandro Santin, David P Warshal, Nick M Spirtos, Paul A DiSilvestro, Olga B Ioffe, David Scott Miller
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (9) (2022)
Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J Ansell, Minh H Dinh, Katherine Bell-McGuinn, Xizhi Luo, Gini F Fleming, Michael L Friedlander, Michael A Bookman, Kathleen M Moore, Karina Dahl Steffensen, Robert L Coleman, Elizabeth M Swisher
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paul A DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael L Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke, Charlie Gourley, Amit M Oza, Antonio Gonzáles Martin, Carol Aghajanian, William H Bradley, Cara A Mathews, Joyce F Liu, John McNamara, Elizabeth S Lowe, Mei-Lin Ah-See, Kathleen M Moore, null null
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Debyani Chakravarty, Amber M Johnson, Jeffrey Sklar, Neal I Lindeman, Kathleen M Moore, Shridar Ganesan, Christine M Lovly, Jane Perlmutter, Stacy W Gray, Jimmy Hwang, Christopher H Lieu, Fabrice Andre, Nilofer S Azad, Mitesh J Borad, Laura Tafe, Hans Messersmith, Mark E Robson, Funda Meric-Bernstam
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (11) (2022)
Siqing Fu, Bradley R Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R Wendel Naumann, Robert M Wenham, Rafael D Rosengarten, Laura Benjamin, Erika Paige Hamilton, Kathleen M Moore
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)
Antonio Gonzáles Martin, Ursula A Matulonis, Jacob Korach, Mansoor Raza Mirza, Kathleen M Moore, Xiaohua Wu, Whitney York, Divya Gupta, Stanislav Lechpammer, Bradley J Monk
Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context. Future oncology (London, England) 18 (23) (2022)
Kathleen M Moore, Bradley J Monk
Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patients-Why Do It? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (14) (2022)
Niharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, Ignacio Garrido-Laguna, John H Strickler, Kathleen M Moore, Robert Stagg, Ann M Kapoun, Leonardo Faoro, Sunil Sharma
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
David S Hong, Kathleen M Moore, Johanna C Bendell, Daniel D Karp, Judy S Wang, Susanna V Ulahannan, Suzanne F Jones, Wenjuan Wu, Gregory P Donoho, Yan Ding, Andrew Capen, Aimee Bence Lin, Manish R Patel
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (7) (2021)
Kathleen M Moore, Setsuko K Chambers, Erika P Hamilton, Lee-May Chen, Amit M Oza, Sharad A Ghamande, Gottfried E Konecny, Steven C Plaxe, Daniel L Spitz, Jill J J Geenen, Tiffany A Troso-Sandoval, Janiel M Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F Jones, David R Spigel, Karen A Cadoo
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Kathleen M Moore, David S Hong, Manish R Patel, Shubham Pant, Susanna V Ulahannan, Suzanne Jones, Funda Meric-Bernstam, Judy S Wang, Raid Aljumaily, Erika P Hamilton, Erika S Wittchen, Xuejing Wang, Aimee Bence Lin, Johanna C Bendell
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Targeted oncology 16 (5) (2021)
David M O'Malley, Leslie M Randall, Camille Gunderson Jackson, Robert L Coleman, John L Hays, Kathleen M Moore, R Wendel Naumann, Rodney P Rocconi, Brian M Slomovitz, Krishnansu S Tewari, Marek Ancukiewicz, Waldo Ortuzar Feliu, Bradley J Monk
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future oncology (London, England) 17 (26) (2021)
Kathleen M Moore, Michael A Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Maenpaa, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A Gold, Yolanda Garcia, Sudarshan K Sharma, Christopher J Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana L Molinero, Vidya Maiya, Victor K Khor, Yvonne G Lin, Sandro Pignata
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (17) (2021)
Amit M Oza, Maria Del Pilar Estevez Diz, Eva-Maria Grischke, Marcia Hall, Frederic Marmé, Diane Provencher, Denise S Uyar, Johanne I Weberpals, Robert M Wenham, Naomi Laing, Michael Tracy, Tomoko Freshwater, Mark A Lee, Ji Liu, Jingjun Qiu, Shelonitda Rose, Eric H Rubin, Kathleen M Moore
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (18) (2020)
B J Rimel, Lauren Dockery, Leslie M Randall, Kathleen M Moore
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future oncology (London, England) 16 (33) (2020)
William P Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A Bookman, Monica Brown Jones, Jung-Min Lee, Stéphanie Lheureux, Joyce F Liu, Kathleen M Moore, Carolyn Muller, Patricia Rodriguez, Christine S Walsh, Shannon Neville Westin, Elise C Kohn
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (30) (2020)
Kathleen M Moore, John K Chan, Angeles Alvarez Secord, Manish R Patel, Timothy Callahan, Wei Guo, Zhi-Yi Zhang
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer chemotherapy and pharmacology 83 (4) (2019)
Kathleen M Moore, Hossein Borghaei, David M O'Malley, Woondong Jeong, Shelly M Seward, Todd M Bauer, Raymond P Perez, Ursula A Matulonis, Kelli L Running, Xiaoyan Zhang, Jose F Ponte, Rodrigo Ruiz-Soto, Michael J Birrer
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123 (16) (2017)